EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma

Valentina Fainardi iD, Roberta Carbone, Enrico Vito Buono, Marialaura Menzella, Carlo Caffarelli iD

Cells · 10.07.2026 · 15 (14) · 1246

DOI: 10.3390/cells15141246 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 10.07.2026. Verfasst von Valentina Fainardi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. Hauptthemen laut MEDLINE: Asthma, Interleukin-5, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe treatment-resistant asthma (STRA) in children is often sustained by type 2 inflammation and eosinophil-dependent airway disease that persists despite optimized inhaled therapy and the mitigation of modifiable factors. This review summarizes the clinical and translational evidence on monoclonal antibodies targeting the interleukin-5 (IL-5) axis (anti-IL-5 and anti-IL-5Rα) available in pediatric severe asthma. PubMed/MEDLINE was searched up to January 2026 for English-language studies in patients aged 0–18 years addressing mepolizumab and benralizumab, including randomized trials, high-quality observational studies, meta-analyses, and international guidance. Mepolizumab has the most robust pediatric data, showing consistent reductions in exacerbations and blood eosinophils, and improvements in symptom control and quality of life, with safety broadly comparable to adults. The pediatric evidence for benralizumab is more limited but shows rapid eosinophil depletion, improved outcomes in selected children, and acceptable safety; further trials are ongoing. Overall, IL-5–directed biologics represent a key add-on option for carefully selected children with severe eosinophilic asthma, while pediatric-specific predictors of response, comparative effectiveness, and standardized long-term monitoring and stopping criteria remain priorities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaInterleukin-5Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAnti-Asthmatic AgentsHumansChildEosinophils

Stichwörter der Autor:innen

benralizumabbiologicseosinophilsinterleukin-5mepolizumabpediatric severe asthmasevere treatment-resistant asthma

Substanzen

Interleukin-5Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalbenralizumabmepolizumabIL5 protein, humanAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.

ORCID-Profile: Valentina Fainardi, Carlo Caffarelli

Zitieren

APA

Fainardi, V., Carbone, R., Buono, E. V., Menzella, M., & Caffarelli, C. (2026). Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma. Cells, 15(14), 1246. https://doi.org/10.3390/cells15141246

Vancouver

Fainardi V, Carbone R, Buono EV, Menzella M, Caffarelli C. Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma. Cells. 2026;15(14):1246. doi:10.3390/cells15141246

BibTeX
@article{Fainardi2026,
  author = {Fainardi, Valentina and Carbone, Roberta and Buono, Enrico Vito and Menzella, Marialaura and Caffarelli, Carlo},
  title = {Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {1246},
  doi = {10.3390/cells15141246}
}
Kostenlos starten →